165 related articles for article (PubMed ID: 25339141)
21. Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
Mariappan P; Johnston A; Padovani L; Clark E; Trail M; Hamid S; Hollins G; Simpson H; Thomas BG; Hasan R; Bhatt J; Ahmad I; Nandwani GM; Mitchell IDC; Hendry D;
Eur Urol; 2020 Oct; 78(4):520-530. PubMed ID: 32690321
[TBL] [Abstract][Full Text] [Related]
22. Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome.
Turker P; Bostrom PJ; Wroclawski ML; van Rhijn B; Kortekangas H; Kuk C; Mirtti T; Fleshner NE; Jewett MA; Finelli A; Kwast TV; Evans A; Sweet J; Laato M; Zlotta AR
BJU Int; 2012 Sep; 110(6):804-11. PubMed ID: 22321341
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer.
Williams SB; Shan Y; Ray-Zack MD; Hudgins HK; Jazzar U; Tyler DS; Freedland SJ; Swanson TA; Baillargeon JG; Hu JC; Kaul S; Kamat AM; Gore JL; Mehta HB
JAMA Surg; 2019 Aug; 154(8):e191629. PubMed ID: 31166593
[TBL] [Abstract][Full Text] [Related]
24. Clinical pitfalls in diagnosis of nonmuscle-invasive bladder cancer.
Serretta V; Scalici Gesolfo C
Urologia; 2015 Oct; 82 Suppl 2():S1-4. PubMed ID: 26481718
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of risk of muscle invasion, perivesical and/or lymph node affectation by diffusion-weighted magnetic nuclear resonance in the patient who is a candidate for radical cystectomy.
Lista F; Andrés G; Cáceres F; Ramón de Fata F; Rodríguez-Barbero JM; Angulo JC
Actas Urol Esp; 2013; 37(7):419-24. PubMed ID: 23773823
[TBL] [Abstract][Full Text] [Related]
26. Underutilization of Radical Cystectomy Among Patients Diagnosed with Clinical Stage T2 Muscle-invasive Bladder Cancer.
Williams SB; Huo J; Chamie K; Hu JC; Giordano SH; Hoffman KE; Dinney CPN; Kamat AM; Shih YT
Eur Urol Focus; 2017 Apr; 3(2-3):258-264. PubMed ID: 28753760
[TBL] [Abstract][Full Text] [Related]
27. Sensitivity to chemoradiation predicts development of metastasis in muscle-invasive bladder cancer patients.
Koga F; Numao N; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
Urol Oncol; 2013 Oct; 31(7):1270-5. PubMed ID: 22386622
[TBL] [Abstract][Full Text] [Related]
28. Long-term Outcomes from Re-resection for High-risk Non-muscle-invasive Bladder Cancer: A Potential to Rationalize Use.
Gordon PC; Thomas F; Noon AP; Rosario DJ; Catto JWF
Eur Urol Focus; 2019 Jul; 5(4):650-657. PubMed ID: 29089252
[TBL] [Abstract][Full Text] [Related]
29. The impact of low- versus high-intensity surveillance cystoscopy on surgical care and cancer outcomes in patients with high-risk non-muscle-invasive bladder cancer (NMIBC).
Rezaee ME; Lynch KE; Li Z; MacKenzie TA; Seigne JD; Robertson DJ; Sirovich B; Goodney PP; Schroeck FR
PLoS One; 2020; 15(3):e0230417. PubMed ID: 32203532
[TBL] [Abstract][Full Text] [Related]
30. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K
BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
[TBL] [Abstract][Full Text] [Related]
31. Use of radical cystectomy for patients with invasive bladder cancer.
Gore JL; Litwin MS; Lai J; Yano EM; Madison R; Setodji C; Adams JL; Saigal CS;
J Natl Cancer Inst; 2010 Jun; 102(11):802-11. PubMed ID: 20400716
[TBL] [Abstract][Full Text] [Related]
32. Detrusor Muscle in TUR-Derived Bladder Tumor Specimens: Can We Actually Improve the Surgical Quality?
Capogrosso P; Capitanio U; Ventimiglia E; Boeri L; Briganti A; Colombo R; Montorsi F; Salonia A
J Endourol; 2016 Apr; 30(4):400-5. PubMed ID: 26597334
[TBL] [Abstract][Full Text] [Related]
33. Down-staging (Beukers W; Meijer T; Vissers CJ; Boormans JL; Zwarthoff EC; van Leenders GJ
Virchows Arch; 2012 Aug; 461(2):149-56. PubMed ID: 22777576
[TBL] [Abstract][Full Text] [Related]
34. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.
Mmeje CO; Guo CC; Shah JB; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol; 2016 Nov; 70(5):778-785. PubMed ID: 26922408
[TBL] [Abstract][Full Text] [Related]
35. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
36. Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy.
Contieri R; Tan WS; Grajales V; Hensley PJ; Martini A; Bree K; Myers A; Nogueras-Gonzalez G; Navai N; Dinney CP; Guo C; Kamat AM
BJU Int; 2024 Jun; 133(6):733-741. PubMed ID: 38374533
[TBL] [Abstract][Full Text] [Related]
37. Evaluating the efficacy of secondary transurethral resection of the bladder for high-grade Ta tumors.
Lee K; Jeong SH; Yoo SH; Ku JH
Investig Clin Urol; 2022 Jan; 63(1):14-20. PubMed ID: 34983118
[TBL] [Abstract][Full Text] [Related]
38. Use of radical cystectomy as initial therapy for the treatment of high-grade T1 urothelial carcinoma of the bladder: a SEER database analysis.
Canter D; Egleston B; Wong YN; Smaldone MC; Simhan J; Greenberg RE; Uzzo RG; Kutikov A
Urol Oncol; 2013 Aug; 31(6):866-70. PubMed ID: 21906968
[TBL] [Abstract][Full Text] [Related]
39. Role of Inter-Observer Variability and Quantification of Muscularis Propria in the Pathological Staging of Bladder Cancer.
Giunchi F; Panzacchi R; Capizzi E; Schiavina R; Brunocilla E; Martorana G; D'Errico A; Fiorentino M
Clin Genitourin Cancer; 2016 Aug; 14(4):e307-12. PubMed ID: 26874973
[TBL] [Abstract][Full Text] [Related]
40. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.
Sternberg IA; Keren Paz GE; Chen LY; Herr HW; Dalbagni G
BJU Int; 2013 Jul; 112(1):54-9. PubMed ID: 23146082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
